Asterias Biotherapeutics (AST) Reports In-Line Q3 EPS, Beats on Revenues

Asterias Biotherapeutics (NYSE: AST) reported Q3 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $1.69 million versus the consensus estimate of $1.48 million.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79